Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In global health governance, the balance between accessibility to essential medicines and the research and development of pharmaceuticals has been a long-standing issue. Because of the diverged national interests, the developed and developing countries pursue different strategies in their negotiations at various global health governance platforms. This study examines the flexible clauses in the TRIPS agreement and the different standpoints of both developed and developing countries, and proposes that China should take full advantage of the flexible clauses in its global health governance to protect the interests of developing countries.


Journal article


Chinese Journal of New Drugs

Publication Date





976 - 984